Related Experiment Videos
Genetic toxicity and potential carcinogenicity of taxol
Abstract:
The activity of the antineoplastic agent taxol depends upon its ability to inhibit tubulin disassembly in dividing cells. We show here that taxol gives a strong positive response in the mouse bone marrow micronucleus assay. This is the first report of its genetic toxicity. The majority of antineoplastic agents are carcinogenic to humans, and the majority of human carcinogens are active in the mouse bone marrow micronucleus assay. The present data therefore indicate a carcinogenic potential of taxol for humans, which should be considered in the risk-benefit analysis of its increasing clinical use.
Insights
Taxol, an antineoplastic agent, shows genetic toxicity in a mouse bone marrow micronucleus assay. This suggests potential human carcinogenicity, requiring risk-benefit consideration for its clinical use.
Area of Science:
- Oncology
- Genetics
- Toxicology
Background:
- Taxol (paclitaxel) is an antineoplastic agent crucial for cancer treatment.
- Its mechanism involves inhibiting tubulin disassembly in dividing cells.
- Many antineoplastic drugs and human carcinogens are positive in the mouse bone marrow micronucleus assay.
Purpose of the Study:
- To evaluate the genetic toxicity of Taxol using the mouse bone marrow micronucleus assay.
- To assess the potential carcinogenic risk of Taxol in humans based on its genotoxicity findings.
Main Methods:
- The study utilized the mouse bone marrow micronucleus assay to detect genetic damage.
- Taxol's response in this established genotoxicity test was analyzed.
Main Results:
- Taxol demonstrated a strong positive response in the mouse bone marrow micronucleus assay.
- This marks the first reported instance of Taxol's genetic toxicity.
Conclusions:
- The positive genotoxicity results for Taxol indicate a potential carcinogenic risk to humans.
- This finding necessitates careful consideration in the risk-benefit analysis of Taxol's ongoing clinical application.